Analysis of prognostic factors in patients with brain metastases affecting survival

Abstract Introduction Brain metastases (BM) are associated with dismal prognosis as they cause significant morbidity and affect the quality of life of patients. Management of BM depends on the following factors: age, patient performance, size and the number of lesions, location of the tumor, comorbi...

Full description

Bibliographic Details
Main Authors: Sweety Gupta, Sumit Singh, Atokali Chophy, Sharanya Nair, Rachit Ahuja, K. Kusum, Deepa Joseph, Rajnish Arora, Amit Gupta, Manoj Gupta
Format: Article
Language:English
Published: SpringerOpen 2022-11-01
Series:Journal of the Egyptian National Cancer Institute
Subjects:
Online Access:https://doi.org/10.1186/s43046-022-00146-z
_version_ 1811328715642109952
author Sweety Gupta
Sumit Singh
Atokali Chophy
Sharanya Nair
Rachit Ahuja
K. Kusum
Deepa Joseph
Rajnish Arora
Amit Gupta
Manoj Gupta
author_facet Sweety Gupta
Sumit Singh
Atokali Chophy
Sharanya Nair
Rachit Ahuja
K. Kusum
Deepa Joseph
Rajnish Arora
Amit Gupta
Manoj Gupta
author_sort Sweety Gupta
collection DOAJ
description Abstract Introduction Brain metastases (BM) are associated with dismal prognosis as they cause significant morbidity and affect the quality of life of patients. Management of BM depends on the following factors: age, patient performance, size and the number of lesions, location of the tumor, comorbidities, primary tumor type, and extracranial disease burden. In the present study, the pattern of occurrence, clinical characteristics, treatment outcome of brain metastases, and factors, tumor characteristics, and treatment that may impact BM patients’ overall survival were analyzed. Methods Retrospective analysis of medical records of 116 patients with histologically proven primary site solid tumors with brain metastases was done in the present study. Clinicoradiological and pathological parameters were documented. The relationship between variables and outcome was assessed by univariate analysis using the Cox proportional regression model to reach a significance of p < 0.05, to determine independent predictors of overall survival. Results One hundred sixteen patients of BM from various solid malignancies were included. Age ranged from 18 to 81 years (median 53.5). One hundred four patients received WBRT with a dose range of 8–40Gy/1–15fr, 7 received SRS with a dose of 18–24Gy depending on the size of the metastatic lesion, and 2 received SRT 27–33Gy/3fr. At the time of final analysis, 47 patients with BM had expired, 60 were lost to follow-up, and 9 were alive. Median survival was 8.25 (0.5–32.5 months) months. Female gender (χ 2 = 8.423; p = 0.015), RPA I (χ 2 = 9.353; p = 0.05), and metachronous BM (χ 2 = 3.793; p = 0.03) were associated with better survival. Patients with age 41–50 years, adenocarcinoma lung histology, and supratentorial location survived more than 2 years but did not show any statistical significance. Conclusion Brain metastases portend a very dismal prognosis. Certain clinicoradiological and pathologic factors have been identified to affect survival. More prospective multicentric trials, with a larger sample size, need to be conducted to assess the benefit of radiation in patients with limited life expectancy and identify prognostic and predictive factors for survival.
first_indexed 2024-04-13T15:30:56Z
format Article
id doaj.art-64265ffb892547dcacfdbe92f722069a
institution Directory Open Access Journal
issn 2589-0409
language English
last_indexed 2024-04-13T15:30:56Z
publishDate 2022-11-01
publisher SpringerOpen
record_format Article
series Journal of the Egyptian National Cancer Institute
spelling doaj.art-64265ffb892547dcacfdbe92f722069a2022-12-22T02:41:23ZengSpringerOpenJournal of the Egyptian National Cancer Institute2589-04092022-11-013411710.1186/s43046-022-00146-zAnalysis of prognostic factors in patients with brain metastases affecting survivalSweety Gupta0Sumit Singh1Atokali Chophy2Sharanya Nair3Rachit Ahuja4K. Kusum5Deepa Joseph6Rajnish Arora7Amit Gupta8Manoj Gupta9Department of Radiation Oncology, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshCollege of Nursing, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshDepartment of Neurosurgery, AIIMS RishikeshDepartment of Surgery, AIIMS RishikeshDepartment of Radiation Oncology, AIIMS RishikeshAbstract Introduction Brain metastases (BM) are associated with dismal prognosis as they cause significant morbidity and affect the quality of life of patients. Management of BM depends on the following factors: age, patient performance, size and the number of lesions, location of the tumor, comorbidities, primary tumor type, and extracranial disease burden. In the present study, the pattern of occurrence, clinical characteristics, treatment outcome of brain metastases, and factors, tumor characteristics, and treatment that may impact BM patients’ overall survival were analyzed. Methods Retrospective analysis of medical records of 116 patients with histologically proven primary site solid tumors with brain metastases was done in the present study. Clinicoradiological and pathological parameters were documented. The relationship between variables and outcome was assessed by univariate analysis using the Cox proportional regression model to reach a significance of p < 0.05, to determine independent predictors of overall survival. Results One hundred sixteen patients of BM from various solid malignancies were included. Age ranged from 18 to 81 years (median 53.5). One hundred four patients received WBRT with a dose range of 8–40Gy/1–15fr, 7 received SRS with a dose of 18–24Gy depending on the size of the metastatic lesion, and 2 received SRT 27–33Gy/3fr. At the time of final analysis, 47 patients with BM had expired, 60 were lost to follow-up, and 9 were alive. Median survival was 8.25 (0.5–32.5 months) months. Female gender (χ 2 = 8.423; p = 0.015), RPA I (χ 2 = 9.353; p = 0.05), and metachronous BM (χ 2 = 3.793; p = 0.03) were associated with better survival. Patients with age 41–50 years, adenocarcinoma lung histology, and supratentorial location survived more than 2 years but did not show any statistical significance. Conclusion Brain metastases portend a very dismal prognosis. Certain clinicoradiological and pathologic factors have been identified to affect survival. More prospective multicentric trials, with a larger sample size, need to be conducted to assess the benefit of radiation in patients with limited life expectancy and identify prognostic and predictive factors for survival.https://doi.org/10.1186/s43046-022-00146-zMetastasesBrainWhole brain radiotherapySurvival
spellingShingle Sweety Gupta
Sumit Singh
Atokali Chophy
Sharanya Nair
Rachit Ahuja
K. Kusum
Deepa Joseph
Rajnish Arora
Amit Gupta
Manoj Gupta
Analysis of prognostic factors in patients with brain metastases affecting survival
Journal of the Egyptian National Cancer Institute
Metastases
Brain
Whole brain radiotherapy
Survival
title Analysis of prognostic factors in patients with brain metastases affecting survival
title_full Analysis of prognostic factors in patients with brain metastases affecting survival
title_fullStr Analysis of prognostic factors in patients with brain metastases affecting survival
title_full_unstemmed Analysis of prognostic factors in patients with brain metastases affecting survival
title_short Analysis of prognostic factors in patients with brain metastases affecting survival
title_sort analysis of prognostic factors in patients with brain metastases affecting survival
topic Metastases
Brain
Whole brain radiotherapy
Survival
url https://doi.org/10.1186/s43046-022-00146-z
work_keys_str_mv AT sweetygupta analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT sumitsingh analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT atokalichophy analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT sharanyanair analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT rachitahuja analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT kkusum analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT deepajoseph analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT rajnisharora analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT amitgupta analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival
AT manojgupta analysisofprognosticfactorsinpatientswithbrainmetastasesaffectingsurvival